
        <!DOCTYPE html>
        <html>
        <head>
            <title>ULTRAGENYX PHARMACEUTICAL INC. (RARE) - Articles</title>
            <meta name="viewport" content="width=device-width, initial-scale=1.0">
            <style>
                :root {
                    --primary-color: #000000;
                    --secondary-color: #666666;
                    --accent-color: #d5001c;
                    --text-color: #2c3e50;
                    --border-color: #e0e0e0;
                    --hover-color: #f8f9fa;
                }
                
                body { 
                    font-family: "Porsche Next", "Segoe UI", Arial, sans-serif;
                    margin: 0;
                    padding: 0;
                    color: var(--text-color);
                    background-color: #f5f6fa;
                    line-height: 1.6;
                }
                
                .header {
                    background: linear-gradient(135deg, #000 0%, #1a1a1a 100%);
                    padding: 25px 0;
                    box-shadow: 0 2px 10px rgba(0,0,0,0.2);
                    position: sticky;
                    top: 0;
                    z-index: 1000;
                    backdrop-filter: blur(10px);
                }
                
                .header::before {
                    content: '';
                    position: absolute;
                    top: 0;
                    left: 0;
                    right: 0;
                    bottom: 0;
                    background: radial-gradient(circle at 30% 50%, rgba(255,255,255,0.08) 0%, rgba(255,255,255,0) 70%);
                    pointer-events: none;
                }
                
                .header-content {
                    max-width: 1400px;
                    margin: 0 auto;
                    padding: 0 30px;
                    display: flex;
                    justify-content: space-between;
                    align-items: center;
                }
                
                .header-title {
                    font-size: 28px;
                    font-weight: 300;
                    color: #fff;
                    margin: 0;
                    letter-spacing: 1px;
                }
                
                .back-btn {
                    background: rgba(255,255,255,0.1);
                    border: 1px solid rgba(255,255,255,0.2);
                    padding: 10px 20px;
                    color: #fff;
                    text-decoration: none;
                    font-size: 14px;
                    border-radius: 4px;
                    transition: all 0.3s ease;
                    backdrop-filter: blur(5px);
                }
                
                .back-btn:hover {
                    background: rgba(255,255,255,0.2);
                    transform: translateY(-2px);
                }
                
                .container {
                    max-width: 1400px;
                    margin: 40px auto;
                    padding: 0 30px;
                }
                
                .stats-container {
                    display: grid;
                    grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
                    gap: 20px;
                    margin-bottom: 40px;
                }
                
                .stat-card {
                    background: #fff;
                    border-radius: 12px;
                    padding: 25px;
                    text-align: center;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: transform 0.3s ease;
                }
                
                .stat-card:hover {
                    transform: translateY(-5px);
                }
                
                .stat-value {
                    font-size: 32px;
                    font-weight: 300;
                    color: var(--primary-color);
                    margin-bottom: 10px;
                }
                
                .stat-label {
                    font-size: 14px;
                    color: var(--secondary-color);
                    text-transform: uppercase;
                    letter-spacing: 1px;
                }
                
                .articles-grid {
                    display: grid;
                    grid-template-columns: repeat(auto-fill, minmax(400px, 1fr));
                    gap: 30px;
                    margin-top: 40px;
                }
                
                .article-card {
                    background: #fff;
                    border-radius: 12px;
                    overflow: hidden;
                    box-shadow: 0 4px 20px rgba(0,0,0,0.08);
                    transition: all 0.3s ease;
                }
                
                .article-card:hover {
                    transform: translateY(-5px);
                }
                
                .article-content {
                    padding: 25px;
                }
                
                .article-title {
                    font-size: 18px;
                    font-weight: 400;
                    margin: 0 0 15px;
                    line-height: 1.4;
                }
                
                .article-title a {
                    color: var(--primary-color);
                    text-decoration: none;
                    transition: color 0.2s ease;
                }
                
                .article-title a:hover {
                    color: var(--accent-color);
                }
                
                .article-meta {
                    display: flex;
                    align-items: center;
                    gap: 20px;
                    margin-bottom: 15px;
                    font-size: 14px;
                    color: var(--secondary-color);
                }
                
                .article-sentiment {
                    padding: 4px 12px;
                    border-radius: 20px;
                    font-weight: 500;
                    font-size: 14px;
                }
                
                .article-sentiment.positive {
                    background: rgba(40,167,69,0.1);
                    color: #28a745;
                }
                
                .article-sentiment.negative {
                    background: rgba(220,53,69,0.1);
                    color: #dc3545;
                }
                
                .article-sentiment.neutral {
                    background: rgba(108,117,125,0.1);
                    color: #6c757d;
                }
                
                .article-summary {
                    font-size: 14px;
                    color: var(--text-color);
                    line-height: 1.6;
                    margin-top: 15px;
                    opacity: 0.8;
                }
                
                @media (max-width: 768px) {
                    .header-content {
                        padding: 0 20px;
                    }
                    
                    .header-title {
                        font-size: 20px;
                    }
                    
                    .container {
                        padding: 0 20px;
                        margin: 20px auto;
                    }
                    
                    .articles-grid {
                        grid-template-columns: 1fr;
                        gap: 20px;
                    }
                    
                    .stat-card {
                        padding: 20px;
                    }
                    
                    .stat-value {
                        font-size: 28px;
                    }
                }
            </style>
        </head>
        <body>
            <div class="header">
                <div class="header-content">
                    <h1 class="header-title">ULTRAGENYX PHARMACEUTICAL INC. (RARE)</h1>
                    <a href="sentiment_report_latest.html" class="back-btn">← Back to Dashboard</a>
                </div>
            </div>
            
            <div class="container">
                <div class="stats-container">
                    <div class="stat-card">
                        <div class="stat-value">7</div>
                        <div class="stat-label">Total Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">2</div>
                        <div class="stat-label">Positive Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">2</div>
                        <div class="stat-label">Negative Articles</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">-0.00</div>
                        <div class="stat-label">Average Sentiment</div>
                    </div>
                </div>
                
                <div class="articles-grid">
        
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=7eea2b063649c705e1bda52cf61e65a1eb2c2d11d38cc9a5feb51bafde6381da" target="_blank" rel="noopener noreferrer">Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-06-03</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=12b3980273ac4ec4b9374cc0f1f562a03f16d2c531837c9712280b70815be0ad" target="_blank" rel="noopener noreferrer">3 High Growth Tech Stocks In The US Market</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-21</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.24
                                </span>
                            </div>
                            <div class="article-summary">As the U.S. market navigates a complex landscape with the S&P 500 experiencing slight declines and Treasury yields on the rise, investors are closely monitoring legislative developments that could imp...</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=cc11b408c9e40aa65527c1139b34742b06e2715e49ddd22421106bf8fa50dd87" target="_blank" rel="noopener noreferrer">Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-20</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.00
                                </span>
                            </div>
                            <div class="article-summary">NOVATO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare...</div>
                        </div>
                    </div>
            
                    <div class="article-card positive">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=accab8e8a6f3e6eff3dbf4c94943557f8e5150e4a3f2f7ae1879580110103eca" target="_blank" rel="noopener noreferrer">Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-14</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment positive">
                                    0.37
                                </span>
                            </div>
                            <div class="article-summary">NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company’s approach to corporate responsibility. T...</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=976d4a506fc7942b50b4ad82990b765fd426f169cd51001470755ab3c34b0472" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-09</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.55
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) shareholders are probably feeling a little disappointed, since its......</div>
                        </div>
                    </div>
            
                    <div class="article-card neutral">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=6fa330ac558796c9f0c2d528fd9a0a93d9c79e5c0465d47eb0366c70b57d5686" target="_blank" rel="noopener noreferrer">Ultragenyx Pharmaceutical First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-08</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment neutral">
                                    0.20
                                </span>
                            </div>
                            <div class="article-summary">Ultragenyx Pharmaceutical ( NASDAQ:RARE ) First Quarter 2025 Results Key Financial Results Revenue: US$139.3m (up 28......</div>
                        </div>
                    </div>
            
                    <div class="article-card negative">
                        <div class="article-content">
                            <h3 class="article-title">
                                <a href="https://finnhub.io/api/news?id=4d3679eab12ea9061782ca42469a9eabdf94a255ed9681bed7198c79fdb3d8f2" target="_blank" rel="noopener noreferrer">Ultragenyx price target lowered to $100 from $140 at Truist</a>
                            </h3>
                            <div class="article-meta">
                                <span>2025-05-08</span>
                                <span>Yahoo</span>
                                <span class="article-sentiment negative">
                                    -0.27
                                </span>
                            </div>
                            <div class="article-summary">Truist lowered the firm’s price target on Ultragenyx (RARE) to $100 from $140 and keeps a Buy rating on the shares. The company’s Q1 results were in-line and the management reiterated its FY25 revenue...</div>
                        </div>
                    </div>
            
                </div>
            </div>
        </body>
        </html>
        